Noom Med review: is it worth it?

What is Noom Med and how does it actually work?

Noom Med is the prescription arm of Noom, the behavior-change app best known for its psychology-driven food logging. Launched as a medical offering in 2022 and significantly expanded in 2024–2025, it is a telehealth platform: there are no physical clinics. The entire process happens through the app and asynchronous (and some live) messaging.

The flow is consistent across plans:

1. Online intake. You complete a health questionnaire covering weight history, current medications, medical conditions, and goals. Noom collects height/weight to calculate BMI.
2. Clinician review. A licensed clinician (physician, nurse practitioner, or physician assistant, depending on your state) reviews your case and decides whether a GLP-1 is appropriate. This is an asynchronous review in most cases, not a video physical exam.
3. Prescription and routing. If approved, you are routed down one of two very different paths: a *brand-name* prescription sent to a pharmacy (where your insurance, if any, applies), or a *compounded* medication shipped directly from a partner compounding pharmacy.
4. Ongoing care. You get the Noom app, 1:1 coaching, unlimited messaging with a care team, dose titration, refill management, and side-effect support.

The single most important thing to understand before comparing prices: Noom Med is two products wearing one brand. The brand-name path is a prescription-and-coaching service where the drug cost is separate. The compounded path bundles the medication into the monthly fee. Conflating them is the most common mistake in reviews of this service.

What medications does Noom Med prescribe?

Noom Med's medication menu (as advertised in 2025–2026) spans several categories:

• Brand-name GLP-1/GIP injectables — Wegovy (semaglutide), Zepbound (tirzepatide), and Ozempic (semaglutide, FDA-approved for type 2 diabetes, prescribed off-label for weight in some cases). These are FDA-approved finished drugs. Noom prescribes them and helps with insurance; you obtain them from a retail or specialty pharmacy.
• Compounded GLP-1 programs — marketed as "Noom GLP-1Rx," "GLP-1Rx Plus," and the "Microdose GLP-1Rx" program. These use compounded semaglutide (and tirzepatide for the "Plus" GIP/GLP-1 option) sourced from compounding pharmacies, with the medication included in the price.
• Oral options — metformin (which Noom explicitly notes is *not* FDA-approved for weight loss), plus newer oral GLP-1 offerings as they reach market.

The active ingredients in the compounded products — semaglutide and tirzepatide — are the same molecules as the brand drugs. The critical distinction is regulatory, covered in the safety section below.

How well do the underlying drugs work?

This is where Noom Med earns most of its credibility, because the medications it prescribes are genuinely among the most effective obesity treatments ever studied. The efficacy belongs to the *drugs*, not to Noom — but it is real.

• Semaglutide 2.4 mg (Wegovy): In the pivotal STEP 1 trial, adults with obesity lost an average of about 14.9% of body weight over 68 weeks, versus roughly 2.4% on placebo (NEJM 2021, Wilding et al., PMID 33567185).
• Tirzepatide (Zepbound): In SURMOUNT-1, the 15 mg dose produced an average weight reduction of about 20.9% over 72 weeks, versus about 3.1% on placebo (NEJM 2022, Jastreboff et al., PMID 35658024). This was among the largest average reductions reported in a major obesity trial.
• Head-to-head: In SURMOUNT-5, the first major randomized comparison, tirzepatide produced significantly greater weight loss than semaglutide over 72 weeks — about 20.2% versus 13.7% (NEJM 2025, Aronne et al., PMID 40353578) — reinforcing that the "Plus" (tirzepatide) tier is the most potent option Noom offers.

Two honest caveats. First, these numbers come from trials of *full-dose, brand-name* drugs delivered with structured support — not necessarily what every Noom microdose member will experience. Second, weight regain after stopping is well documented: in the STEP 4 withdrawal trial, participants switched to placebo at week 20 regained weight while those who stayed on semaglutide kept losing (JAMA 2021, Rubino et al., PMID 33755728), and the STEP 1 extension found participants regained about two-thirds of their lost weight one year after stopping. This is precisely the gap behavioral programs like Noom claim to fill. Whether the app's psychology curriculum meaningfully changes long-term maintenance versus medication alone is not robustly proven in independent trials.

What about "microdosing"?

Noom's heavily marketed Microdose program uses sub-therapeutic doses (the program has been described as capping well below standard maintenance doses). The pitch is fewer side effects and lower cost. The honest reality: microdosing GLP-1s is not an FDA-recognized or trial-validated dosing strategy for obesity. The randomized evidence above is for standard titrated doses. Lower doses plausibly cause fewer GI side effects, but you should expect proportionally less weight loss than the headline trial figures, and any "lose up to X pounds" marketing claim is a best-case, not an average.

What does Noom Med cost and what do you actually pay?

Pricing is the most confusing part of Noom Med because the advertised "starting at" figures rarely reflect the steady-state monthly cost. Based on Noom's published 2025–2026 plan pages, the structure looks like this:

• Microdose GLP-1Rx — promotional intro around $79 (sometimes shown as $99), then approximately $199/month ongoing, medication included, typically billed quarterly.
• GLP-1Rx (compounded semaglutide) — intro near $129, with ongoing pricing in the ~$129–$279/month range depending on dose and promotion, medication included.
• GLP-1Rx Plus (compounded tirzepatide) — intro around $149 (from $199), then up to roughly $299/month ongoing, medication included. Marketed as the most powerful option.
• Brand-name telehealth (Wegovy/Zepbound/Ozempic) — a low service fee (advertised "starting at $69," sometimes $99–$149) that does not include the drug. The medication is billed separately through your pharmacy/insurance and can range from a modest copay to $1,000+/month at cash price.
• Metformin (oral) — intro ~$69, then ~$99/month.

Plans are generally FSA/HSA eligible and do not require insurance. Key value caveats:

• The billed-quarterly structure means you commit to roughly three months at a time, not a true month-to-month cancel.
• "Starting at" intro prices step up sharply after the first 3–4 week supply. Budget for the *ongoing* number, not the headline.
• On the brand-name path, the Noom fee is almost an afterthought relative to drug cost — if your insurance covers Wegovy/Zepbound, paying Noom mainly buys convenience and coaching you may be able to get from your primary-care physician for less.

Is Noom Med safe and legitimate?

Noom is an established company using licensed clinicians, which puts it ahead of fly-by-night "GLP-1 in your inbox" operations. But the safety picture depends entirely on which path you take.

Brand-name path — well-regulated. You receive an FDA-approved finished drug with a known manufacturing standard and full FDA labeling. The main concerns are the standard GLP-1 risks (below), not product integrity.

Compounded path — meaningfully more caveats. Compounded semaglutide and tirzepatide are not FDA-approved finished products. They are mixed by compounding pharmacies and have not undergone FDA review for safety, efficacy, or manufacturing quality of the finished injectable. This matters more in 2025–2026 than it did during the shortage years:

• The FDA declared the semaglutide shortage resolved on February 21, 2025, and the tirzepatide shortage resolved earlier (late 2024). With shortages over, the legal basis for mass-compounding "copies" of these drugs has largely closed — 503A pharmacies were given until April 22, 2025, and 503B outsourcing facilities until May 22, 2025, to wind down (FDA). Going forward, legitimate compounding is supposed to be limited to genuine clinical needs (e.g., a documented allergy to a branded excipient or a non-standard dose), not cost or preference.
• The FDA has flagged hundreds of adverse-event reports tied to compounded GLP-1s, dosing errors with multi-dose vials, and counterfeit supply, and has issued warning letters to large compounders for sterile-manufacturing deficiencies (FDA).

What this means practically: if Noom is selling you a compounded "microdose" because it's cheaper rather than because you have a specific clinical need, you are accepting a product that bypasses FDA finished-drug review, in a regulatory environment that is actively tightening. Ask exactly which pharmacy fills your prescription, whether it is a 503A or 503B facility, and whether your dose qualifies as a legitimate clinical need.

Side effects, warnings, and contraindications (the drugs themselves)

Regardless of brand or compounded:

• Common: nausea, vomiting, diarrhea, constipation, and abdominal discomfort — usually dose-dependent and worst during titration.
• Serious but less common: pancreatitis, gallbladder disease, and (per the FDA boxed warning on this drug class) thyroid C-cell tumors observed in rodents — the clinical relevance to humans is uncertain but drives contraindications (FDA labels).
• Contraindicated in people with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), and not for use in pregnancy.
• Interactions/cautions: risk of hypoglycemia when combined with insulin or sulfonylureas; delayed gastric emptying can affect absorption of other oral medications.

A purely asynchronous intake is a reasonable screen for most healthy adults but is a thinner safety net than an in-person evaluation for anyone with significant comorbidities. If you have GI disease, prior pancreatitis, gallbladder issues, or take insulin, that warrants a real conversation with a clinician who knows your full history.

Who is Noom Med best for — and who should skip it?

A good fit if you:

• Want the medication *and* a structured behavior-change program in one place, and value the coaching/accountability layer.
• Are uninsured or have a plan that excludes GLP-1s, and want predictable bundled pricing.
• Are an organized self-starter who will actually use the app's lessons, not just the injection.

Probably better served elsewhere if you:

• Have insurance that covers Wegovy or Zepbound — get the prescription from your PCP or an obesity-medicine specialist and skip the markup; the drug is the same.
• Want maximum, evidence-backed results — that means full-dose brand-name tirzepatide/semaglutide with in-person oversight, not a marketing-driven microdose.
• Have meaningful comorbidities that deserve a hands-on clinical evaluation.
• Are uncomfortable with non-FDA-approved compounded injectables now that the shortage justification has ended.

How does Noom Med compare to the alternatives?

• vs. Ro, Hims & Hers, LifeMD, Found, WeightWatchers Clinic: All are telehealth GLP-1 services with similar structures; pricing on compounded vs. brand and the quality of the behavioral program are the main differentiators. Noom's genuine edge is its mature, psychology-based app and coaching — arguably the best behavior-change layer in the category. Its weakness is the same as everyone else's: reliance on compounded drugs that are now harder to justify legally.
• vs. your own doctor + insurance: If covered, this is almost always cheaper and offers in-person oversight. You lose Noom's coaching and convenience.
• vs. cash-pay through the manufacturers: Eli Lilly's direct-to-consumer Zepbound vials and Novo Nordisk's direct Wegovy programs offer FDA-approved drug at fixed cash prices, which can be competitive with — and safer than — compounded bundles for people without coverage.

The bottom line

Noom Med is a credible, well-built telehealth program with arguably the best behavioral-coaching layer in the GLP-1 space, prescribing medications whose efficacy is firmly established (~15% weight loss for semaglutide, ~21% for tirzepatide in pivotal trials). Its value proposition is strongest for organized, uninsured users who genuinely want the coaching-plus-medication bundle and will use the app.

But the honest reservations are real. The headline prices are intro rates that step up to $199–$299/month; billing is quarterly, not truly month-to-month; the "microdose" approach is a marketing construct, not a trial-validated protocol; and the cheaper tiers depend on compounded drugs that are not FDA-approved and that the FDA has been steadily restricting since shortages resolved in early 2025. If you have insurance coverage, getting the same FDA-approved drug through your own physician is usually cheaper and safer. If you don't, weigh Noom's compounded bundle against manufacturer direct-pay programs that supply the approved product. The medications work; whether Noom is the right way to get them depends on your insurance, your tolerance for compounded products, and how much you'll actually use the coaching you're paying for.